Mesoblast (MESO) EBT Growth (1y) (2015 - 2023)

Mesoblast (MESO) EBT Growth (1y) (2015 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 8.48%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.60%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 88.57%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 213.87%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 76.48%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -12.04%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 530.43%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 96.45%
10 Mesoblast 2.01 Bn 1.87 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 -2.10%
Mar 31, 2023 12.65%
Dec 31, 2022 5.64%
Sep 30, 2022 25.40%
Jun 30, 2022 2.79%
Mar 31, 2022 19.79%
Dec 31, 2021 -1.59%
Sep 30, 2021 10.16%
Jun 30, 2021 38.31%
Mar 31, 2021 -54.56%
Dec 31, 2020 4.60%
Sep 30, 2020 -240.80%
Jun 30, 2020 -50.05%
Mar 31, 2020 36.64%
Dec 31, 2019 2.24%
Sep 30, 2019 63.30%
Jun 30, 2019 -9.37%
Mar 31, 2019 -10.63%
Dec 31, 2018 -184.98%
Sep 30, 2018 -103.72%